Evotec SE / Analyst ratings
Price targets
Analyst ratings
1 analysts rated this company in the past 90 days. The average target price is €6.00, this is a change of -9.9% compared to the current price.
-
Deutsche Bank Research maintains Evotec at 'Hold' - target EUR 6
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Hold" rating for Evotec with a price target of €6. In a study published Thursday, Fynn Scherzler commented on the sale of a site in Toulouse, France, to Sandoz. He called this move a surprise. The company sees it as a milestone in its strategy to streamline its business model. The transaction is expected to directly improve the revenue mix, profit margins, and capital efficiency.
Publication of the original study: July 31, 2025 / Time not specified in the study / CET. First distribution of the original study: July 31, 2025 / 8:02 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains Evotec at 'Hold' - target 7 euros
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Hold" rating for Evotec with a price target of €7. Analyst Fynn Scherzler ventured an outlook on the second-quarter report on Wednesday, but he does not expect any gradual improvement from the drug discovery company. It expects revenue growth of 4 percent and an adjusted operating loss (EBITDA) of €2.8 million./tih/ag
Publication of the original study: July 9, 2025 / Time not specified in the study / CET
First distribution of the original study: July 9, 2025 / 8:08 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research upgrades Evotec to 'Hold' and target to 7 euros
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has upgraded Evotec from "Sell" to "Hold" and raised its price target from EUR 4 to EUR 7. Analyst Fynn Scherzler justified his new investment recommendation by arguing that the drug developer's new targets for 2025 and beyond provide much-needed guidance. He also welcomes the new management team's plan to streamline the company's offering and carefully define its business objectives, the expert wrote in a study released Thursday./edh/la
Publication of the original study: April 24, 2025 / Time not specified in the study / CEST
First distribution of the original study: April 24, 2025 / 7:54 a.m. / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains Evotec at 'Buy' - target 14 euros
HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has maintained its "Buy" rating for Evotec after the company's earnings release, with a price target of €14. The pharmaceutical drug discovery company has presented solid figures for 2024, analyst Christian Ehmann wrote in a quick assessment released Thursday. However, the outlook for earnings is rather cautious compared to expectations. Attention was also focused on the new corporate strategy, which focuses on the group's strengths./mf/mis
Publication of the original study: April 17, 2025 / 8:15 a.m. / CEST
First distribution of the original study: Date not specified in study / Time not specified in study / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains Evotec at 'Sell' - target 4 euros
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Evotec at "Sell" ahead of the company's earnings release, with a price target of €4. The drug discovery company is expected to have generated an 11 percent increase in revenue, analyst Fynn Scherzler wrote in his outlook on the report released on Monday. He estimates an increase in operating profit (EBITDA) of 69 percent./edh/ag
Publication of the original study: March 3, 2025 / Time not specified in the study / CET
First distribution of the original study: March 3, 2025 / 8:30 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains Evotec's 'Buy' rating - 'Best Ideas 2025'
HAMBURG (dpa-AFX Analyst) - Warburg Research has maintained its "Buy" rating for Evotec with a price target of €14. The drug discovery company's stock is among the research firm's "Best Ideas 2025," wrote analyst Christian Ehmann in a study released Thursday. Despite a challenging 2024, Evotec remains well positioned thanks to its broad portfolio and efficiency-oriented reorganization./edh/ajx
Publication of the original study: December 12, 2024 / 1:45 PM / CET
First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains Evotec at 'Sell' - target 4 euros
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research has maintained its rating for Evotec at "Sell" with a price target of EUR 4 following Halozyme's withdrawn bid. All eyes are now on Triton's next possible steps, now that the financial investor has acquired a 10 percent stake in the drug discovery company, wrote analyst Falko Friedrichs in his commentary published on Monday./edh/ag
Publication of the original study: November 25, 2024 / Time not specified in the study / CET
First distribution of the original study: November 25, 2024 / 08:28 / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains Evotec at 'Buy' - target 14 euros
HAMBURG (dpa-AFX Analyser) - The analyst firm Warburg Research has maintained its rating for Evotec at "Buy" with a price target of 14 euros in response to a takeover offer from Halozyme for 11 euros per share. Even given the drug discovery company's current poor situation, he sees Evotec's long-term value at €14, wrote analyst Christian Ehmann in a study published Friday./edh/tih
Publication of the original study: November 15, 2024 / 8:15 a.m. / CET
First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains Evotec at 'Sell' - target 4 euros
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Evotec at "Sell" with a price target of €4 following an announcement by financial investor Triton. While Triton's strategy is unclear, he believes a complete takeover of the drug discovery company is possible, wrote analyst Falko Friedrichs in a study published Tuesday./edh/mis
Publication of the original study: November 12, 2024 / Time not specified in study / CET
First distribution of the original study: November 12, 2024 / 7:59 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains Evotec at 'Sell' - target 4 euros
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Evotec at "Sell" following its quarterly results, with a price target of €4. The drug discovery company's key figures fell short of expectations, wrote analyst Falko Friedrichs in a study published Thursday. Furthermore, the annual outlook is risky./edh/ajx
Publication of the original study: November 7, 2024 / Time not specified in study / CET
First distribution of the original study: November 7, 2024 / 8:05 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains Evotec at 'Buy' - target 14 euros
HAMBURG (dpa-AFX Analyst) - Following its quarterly results, analyst Warburg Research maintained a "Buy" rating on Evotec with a price target of €14. The pharmaceutical drug discovery and development company met expectations and confirmed its outlook, analyst Christian Ehmann wrote in an initial reaction on Wednesday./gl/edh
Publication of the original study: November 6, 2024 / 8:15 a.m. / CET First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
RBC maintains Evotec at 'Outperform' - Target 12 euros
NEW YORK (dpa-AFX Analyst) - Canadian bank RBC has maintained its rating for Evotec at "Outperform" with a price target of €12. To achieve its confirmed annual targets, the drug discovery company needs a "strong fourth quarter," wrote analyst Charles Weston on Wednesday morning following the previous evening's figures./ag/gl
Publication of the original study: November 6, 2024 / 2:04 a.m. / EST First distribution of the original study: November 6, 2024 / 2:04 a.m. / EST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
RBC maintains Evotec at 'Outperform' - Target 12 euros
NEW YORK (dpa-AFX Analyst) - Canadian bank RBC has maintained its rating for Evotec at "Outperform" with a price target of €12. The drug discovery company has scheduled a three-hour third-quarter analyst conference for this Wednesday and has not yet promised any new medium-term targets, analyst Charles Weston wrote in his commentary published Tuesday. He therefore expects the event to provide detailed insights into Evotec's markets and competitive positioning, as well as a presentation of its future strategy./ck/ag
Publication of the original study: November 4, 2024 / 5:30 PM / EST
First distribution of the original study: November 5, 2024 / 12:45 AM / EST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains Evotec at 'Buy' - target 14 euros
HAMBURG (dpa-AFX Analyser) - The analyst firm Warburg Research has maintained its "Buy" rating for Evotec ahead of its quarterly results, with a price target of €14. The drug discovery company is expected to report a decline in earnings (adjusted EBITDA) and a 5.8 percent decline in revenue, analyst Christian Ehmann wrote in a study released Wednesday. Its forecasts are below consensus estimates./edh/bek
Publication of the original study: October 16, 2024 / 8:15 a.m. / CEST
First distribution of the original study: Date not specified in study / Time not specified in study / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains Evotec at 'Sell' - target 4 euros
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained a "sell" rating on Evotec with a price target of €4. The pharmaceutical drug discovery and development company's upcoming quarterly results are likely to be weak, analyst Falko Friedrichs wrote in an outlook published on Tuesday. A significantly better final quarter is needed to achieve its annual targets. This requires the expected savings and operational improvements./gl/tih
Publication of the original study: October 8, 2024 / 8:10 a.m. / CET First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.